Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B

Background: The release of CD30 molecule in the soluble form (sCD30) is considered a feature of Th2 activation and proliferation of the cellular phenotype Th2. Aim: To analyze the immunoregulatory role of sCD30 in the evolution of hepatitis B virus (HBV) infection. Patients and methods: Three study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Monsalve C,Francisca, Romero-A,Tania, Estévez M,Jesús, Costa L,Luciana, Callejas M,Diana
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2001
Materias:	Hepatitis B antigens Hepatitis B antibodies Hepatitis B virus CD30 antigens
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001001100003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872001001100003
record_format	dspace
spelling	oai:scielo:S0034-988720010011000032002-06-12Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis BMonsalve C,FranciscaRomero-A,TaniaEstévez M,JesúsCosta L,LucianaCallejas M,Diana Hepatitis B antigens Hepatitis B antibodies Hepatitis B virus CD30 antigens Background: The release of CD30 molecule in the soluble form (sCD30) is considered a feature of Th2 activation and proliferation of the cellular phenotype Th2. Aim: To analyze the immunoregulatory role of sCD30 in the evolution of hepatitis B virus (HBV) infection. Patients and methods: Three study groups were formed: 15 patients with acute infection by HBV who remitted toward the resolution of the infection; 15 patients who evolved to the carrier state and 15 subjects without clinical history of infection by this or other viruses. The determination of serological markers for the HBV was done by the Microparticles Enzymatic Immunoanalysis techniques (MEIA). The method of double antibody by ELISA was used For sCD30 determination. Results: A significant sCD30 increase (p < 0.05) was observed in patients with acute infection, during the acute phase (135.7 ± 36.7). These values decreased to 16.2 ± 2.5 during the convalescent phase. Patients that evolved to the carrier state, did not experience a rise in sCD30 values (40.2 ± 6.7, 38 ± 9.2 and 36.1 ± 8.3 during the acute phase, at 120 and 240 days respectively). The value in the control group was 34.8 ± 6.7. Conclusions: The group that evolved towards remission experienced a higher activation of the Th2 cellular phenotype, promoting humoral immune response. An inactivity of sCD30 values was observed in the group that evolved to the carrier state (Rev Méd Chile 2001; 129: 1248-52).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.129 n.11 20012001-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001001100003es10.4067/S0034-98872001001100003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Hepatitis B antigens Hepatitis B antibodies Hepatitis B virus CD30 antigens
spellingShingle	Hepatitis B antigens Hepatitis B antibodies Hepatitis B virus CD30 antigens Monsalve C,Francisca Romero-A,Tania Estévez M,Jesús Costa L,Luciana Callejas M,Diana Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B
description	Background: The release of CD30 molecule in the soluble form (sCD30) is considered a feature of Th2 activation and proliferation of the cellular phenotype Th2. Aim: To analyze the immunoregulatory role of sCD30 in the evolution of hepatitis B virus (HBV) infection. Patients and methods: Three study groups were formed: 15 patients with acute infection by HBV who remitted toward the resolution of the infection; 15 patients who evolved to the carrier state and 15 subjects without clinical history of infection by this or other viruses. The determination of serological markers for the HBV was done by the Microparticles Enzymatic Immunoanalysis techniques (MEIA). The method of double antibody by ELISA was used For sCD30 determination. Results: A significant sCD30 increase (p < 0.05) was observed in patients with acute infection, during the acute phase (135.7 ± 36.7). These values decreased to 16.2 ± 2.5 during the convalescent phase. Patients that evolved to the carrier state, did not experience a rise in sCD30 values (40.2 ± 6.7, 38 ± 9.2 and 36.1 ± 8.3 during the acute phase, at 120 and 240 days respectively). The value in the control group was 34.8 ± 6.7. Conclusions: The group that evolved towards remission experienced a higher activation of the Th2 cellular phenotype, promoting humoral immune response. An inactivity of sCD30 values was observed in the group that evolved to the carrier state (Rev Méd Chile 2001; 129: 1248-52).
author	Monsalve C,Francisca Romero-A,Tania Estévez M,Jesús Costa L,Luciana Callejas M,Diana
author_facet	Monsalve C,Francisca Romero-A,Tania Estévez M,Jesús Costa L,Luciana Callejas M,Diana
author_sort	Monsalve C,Francisca
title	Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B
title_short	Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B
title_full	Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B
title_fullStr	Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B
title_full_unstemmed	Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B
title_sort	niveles séricos de la molécula cd30 soluble en la infección por el virus de hepatitis b
publisher	Sociedad Médica de Santiago
publishDate	2001
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001001100003
work_keys_str_mv	AT monsalvecfrancisca nivelessericosdelamoleculacd30solubleenlainfeccionporelvirusdehepatitisb AT romeroatania nivelessericosdelamoleculacd30solubleenlainfeccionporelvirusdehepatitisb AT estevezmjesus nivelessericosdelamoleculacd30solubleenlainfeccionporelvirusdehepatitisb AT costalluciana nivelessericosdelamoleculacd30solubleenlainfeccionporelvirusdehepatitisb AT callejasmdiana nivelessericosdelamoleculacd30solubleenlainfeccionporelvirusdehepatitisb
_version_	1718435999610044416

Niveles séricos de la molécula CD30 soluble en la infección por el virus de hepatitis B

Ejemplares similares